-
2025-522511-42-00
4
2026-05-19
Crohn's disease
-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2025-521792-31-01
5
2026-04-07
Homozygous Familial Hypercholesterolemia (HoFH)
-
2025-521142-22-00
5
2026-03-27
Hereditary Angioedema
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-512486-14-00
5
2026-01-22
Short Bowel Syndrome
-
2025-521352-38-00
5
2026-01-16
Hereditary Angioedema
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-520201-39-00
4
2025-08-28
Moderately to Severely Active Ulcerative Colitis
-
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
-
2024-518359-47-00
10
2025-06-17
Acute Myeloid Leukemia
-
2024-517032-22-00
5
2025-06-10
Immune system diseases.
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2025-521936-12-00
5
2026-04-24
Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-522231-34-00
5
2026-03-31
Diabetic Macular Edema
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer